The Spanish Association of Orphan and Ultra Orphan Drugs Laboratories (AELMHU) has appointed Beatriz Perales as the new president of the Association, replacing María José Sánchez, who will remain on the Board of Directors as vice-president after more than three years at the head of the Association.
With a degree in Pharmacy from the Complutense University of Madrid, Beatriz combines her responsibilities at Sobi as Director of Market Access and Institutional Relations with teaching as a lecturer in the Masters in Medical Affairs at the University of Nebrija and CESIF, as well as in Registration and Access to Medicines and Related Products at the Official College of Pharmacists of Madrid.
In addition to already being part of the Board of Directors since September 2022 as secretary, Perales has an extensive background in the pharmaceutical industry, having held leadership positions in areas such as rare diseases, oncology and immunology in companies such as Ferring, Bristol Myers Squibb, Biogen and Roche, among others.
The new Board of Directors was elected at the Ordinary Assembly, which was held at Takeda's offices last Friday. Joining Beatriz Perales will be María José Sánchez, general manager of CSL Behring in Spain and Portugal, as vice-president; José Luis Moreno, general manager of Ultragenyx in Italy, Spain and Portugal, as secretary; Sergio Bullón, general manager of Alnylam Pharmaceuticals in Spain, who will continue as treasurer; and Iván SilvaMarket Access Director for the Southern Cluster and Managing Director for Spain at Kyowa Kirin, who joins the Board of Directors as a member for the first time.
With this new management team, composed of professionals with extensive experience and recognized prestige in the biotechnology and pharmaceutical sectors, AELMHU reinforces its commitment to improve the health and quality of life of people affected by rare diseases. The Association will continue to highlight the importance of these pathologies and to value research thanks to the contributions of its associated companies.
Access the full press release here.
